Recent Posts / View All Posts
Prospective clinical trial demonstrates that testing for CTCs reveals lung cancer recurrence an average of six months earlier than conventional scans. Results from a prospective clinical trial showed that a…
Liquid Biotech USA Inc. and MolecularMatch Partner to Expedite Cancer Detection and Treatment
Partnership combines cutting-edge, liquid biopsy cancer screening with treatment data and real-time treatment matching.
Liquid Biotech USA is a biotechnology company with a unique and powerful approach to diagnosing cancer; our technology can detect cancer at early stages of the disease.
In addition, the technology is under development as a tool for physicians to employ during and post-treatment, giving guidance in real time to oncologists. We employ a minimally invasive approach that entails analyzing live, circulating tumor cells (CTCs) directly from patient blood, a so-called “liquid biopsy.” The test is rapid, non-invasive and designed to detect the presence of CTCs in the blood when they are present at very low levels; this offers the potential to manage the disease early in development, including before the tumors have seeded distant organs due to shedding from the primary tumor. This novel approach will guide physicians both during treatment, allowing the oncologist to monitor a treatment in real time during chemotherapy, as well as post-treatment, when a patient is in remission but there is the likelihood of recurrence.